Yues International Holdings Group Limited reported an unaudited net loss of RMB 7.13 million for the six months ended 30 June 2026, versus a loss of RMB 3.45 million a year earlier. Total comprehensive expense reached RMB 9.46 million, up from RMB 2.86 million in the prior-year period.

Revenue fell 19.3 % to RMB 149.79 million, driven by a 46.4 % drop in transportation revenue to RMB 79.81 million. Warehousing revenue declined 29.7 % to RMB 5.16 million, and in-plant logistics slipped 3.4 % to RMB 25.88 million. Customisation services contributed RMB 0.50 million, down from RMB 0.74 million.

Partially offsetting the logistics downturn, sales of Traditional Chinese Medicine (TCM), goat milk powder and other products jumped to RMB 38.45 million from RMB 1.94 million, reflecting the Group’s strategic move into healthcare merchandising in late 2025.

Gross profit narrowed due to higher cost of inventories sold of RMB 34.22 million (1H 2025: RMB 1.89 million) related to the expanding TCM business. Sub-contracting expenses decreased to RMB 76.87 million from RMB 137.79 million, paralleling the lower transportation volume. Employee benefits expenses edged down 4.9 % to RMB 25.55 million following cost-control measures. Other income swung to a net loss of RMB 0.53 million (1H 2025: net gain RMB 2.98 million) on reduced loan interest income and a RMB 0.67 million exchange loss.

Finance costs totalled RMB 0.44 million, mainly discount expenses on receivables factoring and lease liabilities. The tax line showed a small credit of RMB 0.03 million (1H 2025: expense RMB 2.17 million).

The balance sheet remained debt-light with total assets of RMB 237.63 million and total liabilities of RMB 45.86 million. Net current assets stood at RMB 166.25 million, supported by cash and cash equivalents of RMB 77.31 million and a RMB 12.00 million time deposit. The Group had no interest-bearing bank borrowings at period end.

During the period Yues International acquired 70 % of Letongtang Pharmaceutical (Hubei) Co., Ltd. for RMB 2.66 million and purchased Hangzhou Leshi Yihang E-Commerce Co., Ltd. for RMB 10,000 to add international freight-forwarding capabilities.

The Board declared no interim dividend.

Looking ahead, management expects continued pressure on traditional logistics due to fierce price competition and subdued downstream demand, while it pursues growth in TCM merchandising, healthcare logistics infrastructure in Jiangxi, and cross-border services via the newly acquired Hangzhou platform.